Improvement in condition-specific and generic quality of life outcomes in patients with knee osteoarthritis following single-injection Synvisc: results from the LOBRAS study

P Kearey; AE Popple; J Warren; T Davis; N Bellamy; E Barui; S Burne; R Cooke; M Craig; P Dalton; M Dekkers; J Edelman; S Fine; G Gamboa; S Hall; A Ibrahim; C Inderjeeth; K Lim; M Mazur; DAF Morgan; P Myers; A Nicoll; D Nicholls; R Paterson; M Shanahan; A Stockman; S Watson

Journal article

Improvement in condition-specific and generic quality of life outcomes in patients with knee osteoarthritis following single-injection Synvisc: results from the LOBRAS study

P Kearey, AE Popple, J Warren, T Davis, N Bellamy, E Barui, S Burne, R Cooke, M Craig, P Dalton, M Dekkers, J Edelman, S Fine, G Gamboa, S Hall, A Ibrahim, C Inderjeeth, K Lim, M Mazur, DAF Morgan Show all

Current Medical Research and Opinion | Published : 2017

DOI: 10.1080/03007995.2016.1260533

Abstract

Objective: To evaluate the effectiveness of viscosupplementation with single-injection hylan G-F20 (Synvisc-One) in knee osteoarthritis (OA), during routine clinical care, in a 52 week observational study. Research design and methods: The LOBRAS study involved a 1 year long, multi-center, quasi-experimental, repeated measures, observational study. Consenting patients in Australia fulfilling inclusion/exclusion criteria under the care of a medical specialist in routine clinical practice were enrolled. Prior to, and for 52 weeks following, intra-articular single-injection hylan G-F20, patients were repeatedly evaluated using the WOMAC NRS4.1 Index and the SF-36 questionnaire. The WOMAC NRS4.1 ..

View full abstract